keyword
MENU ▼
Read by QxMD icon Read
search

cik cytokine induced killer

keyword
https://www.readbyqxmd.com/read/28629761/cytokines-for-the-induction-of-antitumor-effectors-the-paradigm-of-cytokine-induced-killer-cik-cells
#1
Elisa Cappuzzello, Roberta Sommaggio, Paola Zanovello, Antonio Rosato
Cytokine-Induced killer (CIK) cells are raising growing interest in cellular antitumor therapy, as they can be easily expanded with a straightforward and inexpensive protocol, and are safe requiring only GMP-grade cytokines to obtain very high amounts of cytotoxic cells. CIK cells do not need antigen-specific stimuli to be activated and proliferate, as they recognize and destroy tumor cells in an HLA-independent fashion through the engagement of NKG2D. In several preclinical studies and clinical trials, CIK cells showed a reduced alloreactivity compared to conventional T cells, even when challenged across HLA-barriers; only in a few patients, a mild GVHD occurred after treatment with allogeneic CIK cells...
June 3, 2017: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/28611200/dendritic-cell-cytokine-induced-killer-cell-immunotherapy-combined-with-s-1-in-patients-with-advanced-pancreatic-cancer-a-prospective-study
#2
Ni Jiang, Guoliang Qiao, Xiao-Li Wang, Michael A Morse, William R Gwin, Lei Zhou, Yuguang Song, Yanjie Zhao, Feng Chen, Xin-Na Zhou, Lefu Huang, Amy Hobeika, Xin Yi, Xuefeng Xia, Yanfang Guan, Jin Song, Jun Ren, H Kim Lyerly
Purpose: Advanced pancreatic cancer has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine induced killer cells (DC-CIK) administered with the chemotherapy (CT) S-1 in this malignancy. <p> Experimental Design: Consecutive patients (n=47) with advanced pancreatic cancer were treated with either DC-CIK + S-1, DC-CIK alone, S-1 alone, or best supportive care.</p> <p> Results: DC-CIK plus S-1 produced significantly longer median OS and PFS (212 and 136 days) compared with DC-CIK (128 and 85 days), CT (141 and 92 days) or supportive care only (52 and 43 days) (P<0...
June 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28572734/folfox-regimen-plus-dendritic-cells-cytokine-induced-killer-cells-immunotherapy-for-the-treatment-of-colorectal-cancer-a-meta-analysis
#3
Yan Liu, Zhong Zheng, Qixin Zhang, Xinling Zhou, Yikuan Feng, Anquan Yan
PURPOSE: To systematically investigate the efficacy and safety of the combination of FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) regimen and cocultured dendritic cells and cytokine-induced killer cells (DC-CIK) immunotherapy for the treatment of colorectal cancer (CRC). METHODS: Publications reporting the clinical trials' responses or safety of FOLFOX regimen combined with DC-CIK immunotherapy in treating CRC patients were searched in PubMed, Embase, Cochrane Library, China National Knowledge Internet, and Wanfang databases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28557814/significance-of-frequencies-compositions-and-or-antileukemic-activity-of-dc-stimulated-invariant-nkt-nk-and-cik-cells-on-the-outcome-of-patients-with-aml-all-and-cll
#4
Corinna L Boeck, Daniel C Amberger, Fatemeh Doraneh-Gard, Wishnu Sutanto, Thomas Guenther, Joerg Schmohl, Friedhelm Schuster, Helmut Salih, Florian Babor, Arndt Borkhardt, Helga Schmetzer
Invariant natural killer T (iNKT)/natural killer (NK)/cytokine-induced killer (CIK) cells are important for immune surveillance. (I) Novel combinations of antibody 6B11 (targeting the Vα24-Jα18-invariant T-cell receptor) with CD4/CD8/CD1d/Vα24 for iNKT subset detection and "T/NK cell-like"-iNKT subsets were defined. Compared with healthy peripheral blood mononuclear cells (MNC) (significantly) lower proportions of iNKT cells (6B11/6B11CD3/6B11CD161), NK cells (CD3CD56/CD3CD161), and CIK cells (CD3CD56/CD3CD161) were found in peripheral blood MNC from acute myeloid (AML)/acute myeloid, lymphoid (ALL)/chronic lymphoid leukemia (CLL) patients in acute disease stages...
July 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28529563/role-of-nkg2d-in-cytokine-induced-killer-cells-against-lung-cancer
#5
Xiaowei Yin, Xuzhang Lu, Zhang Xiuwen, Zhou Min, Rong Xiao, Zhengdao Mao, Qian Zhang
It has been previously demonstrated that cytokine-induced killer (CIK) cells possess potent cytotoxicity against various cancer cells, including lung cancer cells. However, the mechanism by which CIK cells recognize lung cancer cells has not been understood. The interaction between killer cell lectin like receptor K1 (NKG2D) receptor and NKG2D ligands was demonstrated to serve an important role in target cell killing by natural killer cells. The present study investigated whether NKG2D receptor and NKG2D ligand interactions are involved in the CIK-directed killing of lung cancer cells...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28507788/adaptive-t-cell-responses-induced-by-oncolytic-herpes-simplex-virus-granulocyte-macrophage-colony-stimulating-factor-therapy-expanded-by-dendritic-cell-and-cytokine-induced-killer-cell-adoptive-therapy
#6
Jun Ren, William R Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, Pankaj Agarwal, Amy Hobeika, Erika Crosby, Zachary C Hartman, Michael A Morse, Kevin H Eng, H Kim Lyerly
Purpose: Although local oncolytic viral therapy (OVT) may enhance tumor lysis, antigen release, and adaptive immune responses, systemic antitumor responses post-therapy are limited. Adoptive immunotherapy with autologous dendritic cells (DC) and cytokine-induced killer cells (DC-CIK) synergizes with systemic therapies. We hypothesized that OVT with Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor (HSV-GM-CSF) would induce adaptive T cell responses that could be expanded systemically with sequential DC-CIK therapy...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28474278/cancer-immunotherapy-with-cytokine-induced-killer-cells
#7
Juan J Mata-Molanes, Manuel Sureda González, Belén Valenzuela Jiménez, Elena Mª Martínez Navarro, Antonio Brugarolas Masllorens
Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+). The ready availability of a lymphocyte source, together with the high proliferative rate and potent anti-tumor activity of CIK cells, has allowed their use as immunotherapy in a wide variety of neoplasms. Cytotoxicity mediated by CD3+CD56+ T cells depends on the major histocompatibility antigen (MHC)-independent recognition of tumor cells and the activation of signaling pathways through the natural killer group 2 member D (NKG2D) cell-surface receptor...
May 4, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28468247/cik-cells-and-hdac-inhibitors-in-multiple-myeloma
#8
David Stephan, Hans Weiher, Ingo G H Schmidt-Wolf
Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors...
April 29, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28426690/phenotypic-characterization-and-anticancer-capacity-of-cd8-cytokine-induced-killer-cells-after-antigen-induced-expansion
#9
Jianhua Liu, Lu Wang, Yaoling Wang, Wenjie Zhang, Yilin Cao
Cytokine-induced killer cells (CIK) have been used in clinic for adoptive immunotherapy in a variety of malignant tumors and have improved the prognosis of cancer patients. However, there are individual differences in the CIK cell preparations including the obvious differences in the ratio of effector CIK cells among different cancer patients. Infusion of such heterogeneous immune cell preparation is an important factor that would affect the therapeutic efficacy. We report here the enrichment and expansion of CD8+ cells from CIK cells cultured for one week using magnetic activated cell sorting (MACS)...
2017: PloS One
https://www.readbyqxmd.com/read/28412743/autologous-transplantation-of-cytokine-induced-killer-cells-as-an-adjuvant-therapy-for-hepatocellular-carcinoma-in-asia-an-update-meta-analysis-and-systematic-review
#10
Xiu-Rong Cai, Xing Li, Jin-Xiang Lin, Tian-Tian Wang, Min Dong, Zhan-Hong Chen, Chang-Chang Jia, Ying-Fen Hong, Qu Lin, Xiang-Yuan Wu
BACKGROUND: High recurrence rate after curative treatment is the major problem for hepatocellular carcinoma (HCC). Cytokine-induced killer cells (CIKs) therapy was extensively studied among HCC patients. However, the value of CIKs therapy was controversial. A meta-analysis was performed to investigate the efficacy of adjuvant CIKs after invasive treatments among HCC patients. METHODS: We searched online for literatures studying sequential CIKs therapy for HCC patients...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408841/cytokine-induced-killer-cells-dendritic-cells-and-cytokine-induced-killer-cells-immunotherapy-for-the-treatment-of-esophageal-cancer-in-china-a-meta-analysis
#11
Yan Liu, Ying Mu, Anqi Zhang, Shaoda Ren, Weihua Wang, Jiaping Xie, Yingxin Zhang, Changhui Zhou
BACKGROUND: Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies. Therefore, it is necessary to systematically evaluate the curative efficacy and safety of CIK/DC-CIK immunotherapy as an adjuvant therapy for conventional therapeutic strategies in the treatment of EC. MATERIALS AND METHODS: Clinical trials published before October 2016 and reporting CIK/DC-CIK immunotherapy treatment responses or safety for EC were searched in Cochrane Library, EMBASE, PubMed, Wanfang and China National Knowledge Internet databases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28404886/cytokine-induced-killer-cells-dendritic-cells-cytokine-induced-killer-cells-immunotherapy-combined-with-chemotherapy-for-treatment-of-colorectal-cancer-in-china-a-meta-analysis-of-29-trials-involving-2-610-patients
#12
Lei Zhang, Ying Mu, Anqi Zhang, Jiaping Xie, Shuangfeng Chen, Fang Xu, Weihua Wang, Yingxin Zhang, Shaoda Ren, Changhui Zhou
PURPOSE: To systematically evaluate the efficacy and safety of Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells (CIK/DC-CIK) immunotherapy in treating advanced colorectal cancer (CRC) patients. RESULTS: 29 trials including 2,610 CRC patients were evolved. Compared with chemotherapy alone, the combination of chemotherapy with CIK/DC-CIK immunotherapy significantly prolonged the overall survival rate (OS) and disease-free survival rate (DFS) (1-5 year OS, P < 0...
March 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28360510/efficacy-of-cytokine-induced-killer-cell-infusion-as-an-adjuvant-immunotherapy-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#13
REVIEW
Ruili Yu, Bo Yang, Xiaohua Chi, Lili Cai, Cui Liu, Lei Yang, Xueyan Wang, Peifeng He, Xuechun Lu
This study was designed to evaluate the efficacy and safety of cytokine-induced killer (CIK) cell-based immunotherapy as an adjuvant therapy for hepatocellular carcinoma (HCC). Published studies were identified by searching Medline, Cochrane, EMBASE, and Google Scholar databases with the keywords: cytokine-induced killer cell, hepatocellular carcinoma, and immunotherapy. The outcomes of interest were overall survival, progression-free survival, and disease-free survival. Eight randomized controlled trials (RCTs), six prospective studies, and three retrospective studies were included...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28360017/modification-of-cytokine-induced-killer-cells-with-folate-receptor-alpha-fr%C3%AE-specific-chimeric-antigen-receptors-enhances-their-antitumor-immunity-toward-fr%C3%AE-positive-ovarian-cancers
#14
Shuguang Zuo, Yuqing Wen, Hean Panha, Gongpeng Dai, Liping Wang, Xuequn Ren, Kanda Fu
Folate receptor alpha (FRα) is aberrantly expressed in ovarian cancers but largely absent in normal tissues, and therefore represents an attractive target for immunotherapy. In recent years, modification of T cells with chimeric antigen receptor (CAR) targeting FRα has been reported to improve antitumor immunity of T cells. However, there are limited data regarding CAR-modified cytokine-induced killer (CAR-CIK) cells. In the present study, we modified CIK cells with FRα-specific CARs and investigated their antitumor immunity against ovarian cancers...
May 2017: Molecular Immunology
https://www.readbyqxmd.com/read/28357913/current-update-of-adoptive-immunotherapy-using-cytokine-induced-killer-cells-to-eliminate-malignant-gliomas
#15
REVIEW
Je Il Ryu, Myung Hoon Han, Jin Hwan Cheong, Jae Min Kim, Choong Hyun Kim
The therapeutic outcome for those with malignant glioma is poor, even though diverse therapeutic modalities have been developed. Immunotherapy has emerged as a therapeutic approach for malignant gliomas, making it possible to selectively treat tumors while sparing normal tissue. Here, we review clinical trials of adoptive immunotherapy approaches for malignant gliomas. We also describe a clinical trial that examined the efficacy and safety of autologous cytokine-induced killer (CIK) cells along with concomitant chemoradiotherapy for newly diagnosed glioblastoma...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28352234/dual-functional-capability-of-dendritic-cells-cytokine-induced-killer-cells-in-improving-side-effects-of-colorectal-cancer-therapy
#16
REVIEW
Paula Mosińska, Agata Gabryelska, Malwina Zasada, Jakub Fichna
The aim of cancer therapy is to eradicate cancer without affecting healthy tissues. Current options available for treating colorectal cancer (CRC), including surgery, chemotherapy or radiotherapy, usually elicit multiple adverse effects and frequently fail to completely remove the tumor cells. Thus, there is a constant need for seeking cancer cell-specific therapeutics to improve the course of cancer therapy and reduce the risk of relapse. In this review we elaborate on the mechanisms underlying the immunotherapy with dendritic cells (DCs) and cytokine-induced killer (CIK) cells, and summarize their effectiveness and tolerability available clinical studies...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28337381/hla-e-inhibitor-enhances-the-killing-of-neuroblastoma-stem-cells-by-co-cultured-dendritic-cells-and-cytokine-induced-killer-cells-loaded-with-membrane-based-microparticles
#17
Zijun Zhen, Kaibin Yang, Litong Ye, Zhiyao You, Rirong Chen, Ying Liu, Youjian He
Neuroblastoma stem cells (NSCs) can cause drug resistance and tumor recurrence. This study aimed to enhance the lytic effect of dendritic cells (DCs) co-cultured with cytokine-induced killer (CIK) cells. NSCs were obtained by suspension culture, and DC-CIK cells were loaded with extracted NSC membrane-based microparticles (MMPs) before evaluating the lytic effect of DC-CIK cells on NSCs. After inhibiting the function or expression of human leukocyte antigen-E (HLA-E) in NSCs by anti-HLA-E monoclonal antibody or siRNA, the DC-CIK cell lytic effect on NSCs was re-assessed...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28301281/cell-based-immunotherapy-with-cytokine-induced-killer-cik-cells-from-preparation-and-testing-to-clinical-application
#18
Yiming Meng, Zhifu Yu, Yefeng Wu, Tianzhao Du, Shi Chen, Fanjuan Meng, Nan Su, Yushu Ma, Xiaoxi Li, Sulan Sun, Guirong Zhang
Cell-based immunotherapy holds promise in the quest for the treatment of cancer, having potential synergy with surgery, chemotherapy and radiotherapy. As a novel approach for adoptive cell-based immunotherapy, cytokine-induced killer (CIK) cells have moved from the 'bench to bedside'. CIK cells are a heterogeneous subset of ex-vitro expanded, polyclonal T-effector cells with both natural killer (NK) and T-cell properties, which present potent non-major histocompatibility complex-restricted cytotoxicity against a variety of tumor target cells...
June 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28292730/chemotherapy-in-combination-with-cytokine-induced-killer-cell-transfusion-an-effective-therapeutic-option-for-patients-with-extensive-stage-small-cell-lung-cancer
#19
Jianmin Huang, Quancheng Kan, Lan, Xuan Zhao, Zhen Zhang, Shuangning Yang, Hong Li, Liping Wang, Li Xu, Zhe Cheng, Yi Zhang
BACKGROUND AND AIMS: In the past decade of clinical studies, the combination of chemotherapy with cytokine induced killer (CIK) cell transfusion has confirmed a promised efficacy in several types of cancer. CIK cells are a mixture of T lymphocytes, generated from peripheral blood mononuclear cells induced by multiple cytokines. This study was aimed to evaluate the clinical efficacy of chemotherapy combined with CIK- cell therapy in patients with extensive stage small cell lung cancer (ES SCLC)...
May 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28260039/comparative-investigation-of-the-effects-of-specific-antigen%C3%A2-sensitized-dc%C3%A2-cik-and-dc%C3%A2-ctl-cells-against-b16-melanoma-tumor-cells
#20
COMPARATIVE STUDY
Peng-Tao Ren, Yuan Zhang
The use of personalized adoptive immunotherapy as a potential novel approach is promising in the treatment of tumors resistant to conventional therapies. In the present study, dendritic cell (DC)‑cytokine‑induced killer (CIK) and DC‑cytotoxic lymphocyte (CTL) cells were cultured to examine their phenotype, proliferation and cytotoxicity against B16 melanoma tumor cells. In addition, comparative investigations of the effect of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells were performed in vitro and in vivo...
April 2017: Molecular Medicine Reports
keyword
keyword
103213
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"